Accredited university hospital programme in Iowa City performing bone marrow, stem cell and cord blood transplants and CAR T-cell therapy for blood cancers and related disorders.
This is the transplant and cellular therapy programme of University of Iowa Health Care, based within the Holden Comprehensive Cancer Center in Iowa City. It is a mainstream academic hospital service, not a private regenerative medicine clinic. It treats patients with blood cancers, bone marrow failure and certain solid tumours, in both adults and children.
The programme states it has been performing stem cell transplants since 1980 and has carried out more than 4,000 transplants; these are figures published by the hospital. It offers autologous transplant, in which a patient's own blood-forming stem cells are collected, stored and given back after high-dose treatment, and allogeneic transplant, using cells from a matched donor. Umbilical cord blood transplant is also offered, as are reduced-intensity or mini transplants for patients who cannot tolerate full-strength conditioning.
Beyond transplant, the programme provides chimeric antigen receptor T-cell therapy (CAR T-cell therapy), in which a patient's own immune T cells are genetically modified in a laboratory to recognise cancer, and tumour-infiltrating lymphocyte (TIL) therapy. It is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), an independent body that inspects clinical care, donor management, cell collection, processing, storage and administration. Clinical trials are also run through the programme.
The programme publishes a care team page but the provider list was empty at the time of review. Ask which consultant would lead your care.
The programme is based at University of Iowa Health Care in Iowa City, Iowa, within the Holden Comprehensive Cancer Center. The transplant service telephone number is 1-319-356-4200. It holds reaccreditation from the Foundation for the Accreditation of Cellular Therapy. Interpretation and translation services are referenced on the hospital site, though specific languages are not listed. No dedicated international-patient service is described.
No prices are published. Transplant and CAR T-cell therapy in this setting are normally billed to insurance or public programmes; the hospital links to patient financial resources for help with cost questions.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.